Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s share price was up 6.6% during trading on Tuesday . The stock traded as high as $7.40 and last traded at $7.32, with a volume of 63,726 shares changing hands. The stock had previously closed at $6.87.

Separately, Stifel Nicolaus started coverage on shares of Aldeyra Therapeutics in a research report on Friday, July 1st. They issued a “buy” rating and a $16.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Aldeyra Therapeutics currently has a consensus rating of “Buy” and an average price target of $13.15.

The firm has a 50-day moving average of $5.77 and a 200 day moving average of $5.54. The firm’s market cap is $46.84 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/aldeyra-therapeutics-inc-aldx-trading-up-6-6.html

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Wednesday, August 10th. The biotechnology company reported ($0.41) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.03. Analysts expect that Aldeyra Therapeutics Inc will post ($1.69) earnings per share for the current year.

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Aldeyra Therapeutics by 3.1% in the second quarter. Vanguard Group Inc. now owns 125,125 shares of the biotechnology company’s stock worth $712,000 after buying an additional 3,718 shares in the last quarter. BlackRock Fund Advisors increased its position in shares of Aldeyra Therapeutics by 1,944.6% in the second quarter. BlackRock Fund Advisors now owns 20,630 shares of the biotechnology company’s stock worth $117,000 after buying an additional 19,621 shares in the last quarter. Boxer Capital LLC increased its position in shares of Aldeyra Therapeutics by 361.2% in the second quarter. Boxer Capital LLC now owns 291,230 shares of the biotechnology company’s stock worth $1,657,000 after buying an additional 228,084 shares in the last quarter. FMR LLC increased its position in shares of Aldeyra Therapeutics by 25.0% in the second quarter. FMR LLC now owns 1,797,811 shares of the biotechnology company’s stock worth $10,230,000 after buying an additional 360,000 shares in the last quarter. Finally, Perceptive Advisors LLC increased its position in shares of Aldeyra Therapeutics by 56.4% in the second quarter. Perceptive Advisors LLC now owns 1,940,458 shares of the biotechnology company’s stock worth $11,041,000 after buying an additional 700,000 shares in the last quarter.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

5 Day Chart for NASDAQ:ALDX

Receive News & Ratings for Aldeyra Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.